Reviva Pharmaceuticals raises $30 million for CNS drug development By Investing.com – Canada Boosts
© Reuters. Reviva Prescribed drugs Holdings, Inc., an organization devoted to growing therapies for central nervous system (CNS) ailments, has efficiently raised roughly $30 million via a registered direct providing. The funds are earmarked for advancing analysis and improvement efforts, notably the Part 3 RECOVER-2 trial of brilaroxazine for treating schizophrenia. The providing concerned the…